Key Points
- Director Barry Quart sold 12,528 shares at an average price of $45.27 for a total of $567,142.56, cutting his holding by about 49.96% to 12,546 shares, per an SEC filing.
- The company reported quarterly EPS of $0.23 (miss vs. $0.31 est.) while revenue of $180.86 million beat expectations and rose 61.2% year-over-year.
- KNSA shares opened at $43.52 (down ~3.2%), with a 12-month range of $18.12–$45.50 and a market cap of $3.30 billion; analysts have an average rating of "Moderate Buy" and an average target of $52.33.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director Barry Quart sold 830 shares of the company's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $45.00, for a total transaction of $37,350.00. Following the completion of the sale, the director directly owned 12,546 shares of the company's stock, valued at $564,570. The trade was a 6.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Kiniksa Pharmaceuticals International Trading Down 3.2%
Kiniksa Pharmaceuticals International stock opened at $43.52 on Thursday. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of 96.71 and a beta of 0.06. The stock has a 50 day moving average of $41.80 and a two-hundred day moving average of $38.09. Kiniksa Pharmaceuticals International, plc has a twelve month low of $18.12 and a twelve month high of $45.50.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). The firm had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm's revenue was up 61.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.18) EPS. Equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several analysts recently commented on the stock. The Goldman Sachs Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday, October 29th. Wedbush upped their price target on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an "outperform" rating in a report on Tuesday, January 13th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, November 2nd. Citigroup increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a "buy" rating in a report on Friday, October 17th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $52.33.
Read Our Latest Stock Report on KNSA
Institutional Trading of Kiniksa Pharmaceuticals International
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Amundi purchased a new stake in Kiniksa Pharmaceuticals International during the first quarter worth approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Kiniksa Pharmaceuticals International by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company's stock valued at $507,000 after purchasing an additional 1,002 shares in the last quarter. Millennium Management LLC increased its holdings in Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after purchasing an additional 67,452 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Kiniksa Pharmaceuticals International by 13.6% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 15,410 shares of the company's stock valued at $430,000 after purchasing an additional 1,846 shares during the period. Finally, Robeco Institutional Asset Management B.V. purchased a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth about $233,000. Institutional investors and hedge funds own 53.95% of the company's stock.
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
